Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review-Reference-Cited by-同舟云学术

Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review

Published:2024-05-20 Issue:5 Volume:24 Page:613-629
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Khoirunnisa Sudewi Mukaromah¹²³^ORCID,Suryanegara Fithria Dyah Ayu¹²⁴,Setiawan Didik⁵⁶^ORCID,Postma Maarten Jacobus¹²⁷⁸⁹

Affiliation:

1. Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

2. Research Institute Science in Healthy Aging and healthcaRE, Groningen, the Netherlands

3. Department of Pharmacy, Institut Teknologi Sumatera, Lampung Selatan, Indonesia

4. Department of Pharmacy, Universitas Islam Indonesia, Yogyakarta, Indonesia

5. Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesia

6. Center for Health Economic Studies, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesia

7. Department of Economics, Econometrics and Finance, University of Groningen, Groningen, the Netherlands

8. Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

9. Centre of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia

Funder

Indonesia Endowment Funds for Education

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2352006

Reference100 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

4. The Distinctive Nature of HER2-Positive Breast Cancers

5. High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller